ANI Pharmaceuticals (ANIP) said Thursday it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.
The FDA granted the drug a competitive generic therapy designation, providing ANI with 180 days of market exclusivity, the company said.
Motegrity, or prucalopride, is intended to treat a type of constipation called chronic idiopathic constipation.
Shares of ANI gained more than 1% in recent premarket activity Thursday.
Price: 56.10, Change: +0.82, Percent Change: +1.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.